the next decade in healthcare will look nothing like the last- oncology is experiencing a tidal wave of therapies and technologies that continues to profoundly change the way cancer is diagnosed, treated, and monitored. the arrival of novel and disruptive technologies, precision medicine and emerging technologies, will drive oncology onward and the decisions taken today will have an impact on the landscape over the next decade. industry, regulators, HTA, pricing agencies, health care professionals, researchers and patient advocates must work together to address these challenges and create solutions to overcome these clinical, regulatory, reimbursement and policy hurdles.

as innovations continue to profoundly change the way cancer care is organized and delivered across canada, and globally our goal is to start thinking about these unique challenges now, proactively, so we are better prepared to respond, embrace and implement further disruptive innovations as they continue to make their way in the cancer ecosystem.

blog posts

understanding cancer

cancer is a collection of related diseases that can occur almost anywhere in the body and is characterized by abnormal cell process involving uncontrolled cell growth and proliferation that alters normal cell behaviour. there are over 100 types of cancers, and in all...

if not now, when?

do we want an innovative canada or are we ok with a balanced-book kind of canada? if that isn’t the million dollar question these days. the proposed PMPRB regulations are in stark contrast to some of the initiatives in innovation and life sciences that some of the...

car-t. one year later

on september 5.2018 health canada gave a notice of compliance [NOC] for tisagenlecleucel [kymriah]. it was the first chimeric antigen receptor [car] t-cell therapy to receive regulatory approval in canada. but here we are one year later after health canada’s approval...

managing expectations

car t-cell therapy is the next big cancer treatment hitting the canadian cancer treatment landscape— with one recently approved car t-cell therapy and another on the way for use in specific patients with B-cell acute lymphoblastic leukemia [ALL] and large B-cell...

how car-t is an opportunity for canada

the arrival of car t-cell therapy is disrupting the canadian healthcare system, but it has also offered an opportunity for canada to position itself as a leader in the delivery of car-t cell therapy - circa 6 months ago. the delays in actually providing access to...

biosimilars. the european experience

the cancer collaborative hosted a webinar on June 19 2019 with jatinder harchowal from the NHS whereby he provided insight into the NHS' experience implementing biosimilars in oncology. jatinder spoke during the webinar about the work that was done in england and the...



Today is #WorldCancerDay2022 - let's talk about the huge impact #COVID19 has had on cancer patients, survivors,& families. (Ex:Curtailing cancer screenings & reducing access to operating rooms)

Don't miss @StuartJPeacock's lecture on this topic.

Addressing long-term impacts of the pandemic on cancer care /via @globeandmail

Load More...